Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386996844> ?p ?o ?g. }
- W4386996844 endingPage "9498" @default.
- W4386996844 startingPage "9479" @default.
- W4386996844 abstract "Background: Immune checkpoint inhibitors (ICIs) have shown efficacy in patients with metastatic urothelial cancer (mUC), however, only a small subset of patients could benefit from ICIs. Identifying predictive biomarkers of ICIs in patients with mUC is clinical meaningful for patient stratification and administration. Methods: Clinical and transcriptomic data of mUC patients treated with ICIs from mUC cohort (IMvigor210 study) was utilized to explore the predictive biomarkers. LASSO Cox regression was performed to construct a predictive model. The predictive model was trained and tested in the mUC cohort, and then exploratively tested in clear cell renal cell carcinoma (ccRCC) and melanoma cohorts in which patients also received ICIs regimens. Results: The differentially expressed genes (DEGs) in complement and coagulation cascades pathway (CCCP) were mainly enriched in non-responders of ICIs in the mUC cohort. A CCCP risk score was constructed based on the DEGs in CCCP. Patients with a low-risk score were more responsive to ICIs and had better overall survival (OS) than those with a high-risk score in the training set (HR, 0.38; 95%CI, 0.27-0.53, P<0.001) and the test set (HR, 0.34; 95%CI, 0.17-0.71, P=0.003). The association between the CCCP risk score and OS remained significant in the multivariable cox regression by adjusting PD-L1 expression and TMB (P<0.05). In addition, there was no difference for OS in the bladder cancer patients without ICIs (TCGA-BLCA cohort, HR, 0.76, 95%CI, 0.49-1.18, P=0.22), suggesting a predictive but not prognostic effect of the risk score. For the exploratory analysis, consistent results were observed that low-risk group showed superior OS in ccRCC cohort (HR, 0.52, 95%CI, 0.37-0.75, P<0.001) and melanoma cohort (HR, 0.27, 95%CI, 0.12-0.62, P=0.001). Conclusions: Our study showed that the CCCP risk score is an independent biomarker that predicts the efficacy of ICIs in mUC patients. The patients with a low-risk score tend to have a better response to ICIs and a longer life time probably due to the immune-activated TME. Further studies are needed to validate the clinical utility of the seven-gene signature." @default.
- W4386996844 created "2023-09-25" @default.
- W4386996844 creator A5004343457 @default.
- W4386996844 creator A5038802224 @default.
- W4386996844 creator A5041450037 @default.
- W4386996844 creator A5045926855 @default.
- W4386996844 creator A5050444301 @default.
- W4386996844 creator A5058918418 @default.
- W4386996844 creator A5065264579 @default.
- W4386996844 creator A5071705595 @default.
- W4386996844 creator A5080042508 @default.
- W4386996844 creator A5086664647 @default.
- W4386996844 creator A5087848706 @default.
- W4386996844 creator A5088345060 @default.
- W4386996844 creator A5090029664 @default.
- W4386996844 date "2023-09-24" @default.
- W4386996844 modified "2023-10-13" @default.
- W4386996844 title "Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer" @default.
- W4386996844 cites W1978286264 @default.
- W4386996844 cites W2028033239 @default.
- W4386996844 cites W2035618305 @default.
- W4386996844 cites W2036209716 @default.
- W4386996844 cites W2041399091 @default.
- W4386996844 cites W2060429849 @default.
- W4386996844 cites W2061123122 @default.
- W4386996844 cites W2068839905 @default.
- W4386996844 cites W2076936113 @default.
- W4386996844 cites W2099117852 @default.
- W4386996844 cites W2107429737 @default.
- W4386996844 cites W2130410032 @default.
- W4386996844 cites W2136648677 @default.
- W4386996844 cites W2150633526 @default.
- W4386996844 cites W2179438025 @default.
- W4386996844 cites W2185403011 @default.
- W4386996844 cites W2214074259 @default.
- W4386996844 cites W2412807977 @default.
- W4386996844 cites W2431688277 @default.
- W4386996844 cites W2559804019 @default.
- W4386996844 cites W2593881435 @default.
- W4386996844 cites W2595827275 @default.
- W4386996844 cites W2735725443 @default.
- W4386996844 cites W2754247840 @default.
- W4386996844 cites W2761575992 @default.
- W4386996844 cites W2782485041 @default.
- W4386996844 cites W2785803176 @default.
- W4386996844 cites W2788142646 @default.
- W4386996844 cites W2806064473 @default.
- W4386996844 cites W2886498337 @default.
- W4386996844 cites W2909679049 @default.
- W4386996844 cites W2936221437 @default.
- W4386996844 cites W2942610007 @default.
- W4386996844 cites W2964012416 @default.
- W4386996844 cites W2973129586 @default.
- W4386996844 cites W2974291499 @default.
- W4386996844 cites W2981790403 @default.
- W4386996844 cites W2982426375 @default.
- W4386996844 cites W2986995081 @default.
- W4386996844 cites W2998493318 @default.
- W4386996844 cites W3029490475 @default.
- W4386996844 cites W3045681856 @default.
- W4386996844 cites W3080758793 @default.
- W4386996844 cites W3098118704 @default.
- W4386996844 cites W3102493364 @default.
- W4386996844 cites W3119005666 @default.
- W4386996844 cites W3135656011 @default.
- W4386996844 cites W3167548419 @default.
- W4386996844 cites W3196107865 @default.
- W4386996844 cites W3215879481 @default.
- W4386996844 cites W4200457038 @default.
- W4386996844 cites W4231393120 @default.
- W4386996844 doi "https://doi.org/10.18632/aging.205022" @default.
- W4386996844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37747262" @default.
- W4386996844 hasPublicationYear "2023" @default.
- W4386996844 type Work @default.
- W4386996844 citedByCount "0" @default.
- W4386996844 crossrefType "journal-article" @default.
- W4386996844 hasAuthorship W4386996844A5004343457 @default.
- W4386996844 hasAuthorship W4386996844A5038802224 @default.
- W4386996844 hasAuthorship W4386996844A5041450037 @default.
- W4386996844 hasAuthorship W4386996844A5045926855 @default.
- W4386996844 hasAuthorship W4386996844A5050444301 @default.
- W4386996844 hasAuthorship W4386996844A5058918418 @default.
- W4386996844 hasAuthorship W4386996844A5065264579 @default.
- W4386996844 hasAuthorship W4386996844A5071705595 @default.
- W4386996844 hasAuthorship W4386996844A5080042508 @default.
- W4386996844 hasAuthorship W4386996844A5086664647 @default.
- W4386996844 hasAuthorship W4386996844A5087848706 @default.
- W4386996844 hasAuthorship W4386996844A5088345060 @default.
- W4386996844 hasAuthorship W4386996844A5090029664 @default.
- W4386996844 hasBestOaLocation W43869968441 @default.
- W4386996844 hasConcept C11783203 @default.
- W4386996844 hasConcept C121608353 @default.
- W4386996844 hasConcept C126322002 @default.
- W4386996844 hasConcept C143998085 @default.
- W4386996844 hasConcept C2777472916 @default.
- W4386996844 hasConcept C2777701055 @default.
- W4386996844 hasConcept C2779134260 @default.
- W4386996844 hasConcept C2780352672 @default.